MGC Pharmaceuticals: Expands Phase IIb trial for COVID-19 patients to India
- MGC Pharmaceuticals will expand its Phase IIb clinical trial of ArtemiC in COVID-19 patients to India where case numbers are rising
- Now patients also recruited from Mahatma Gandhi Mission’s Medical College & Hospital in Aurangabad, India
- The trial is assessing the safety and efficacy of the natural anti-inflammatory formulation on the cyclonic storm deterioration of the respiratory system in COVID-19 patients
- Then the formulation of ArtemiC is based on Artemisinin and Curcumin, natural active ingredients with anti-infective
- Additionally, successful completion of a clinical trial in India also required for any future sale of ArtemiC in the country
- MGC Pharmaceuticals closed the day 15 per cent higher with shares priced at 2.3 cents each
